Novel biomarkers for cholangiocarcinoma: how can it enhance diagnosis, prognostication, and investigational drugs? Part-1
| Autor: | Ranu S Sinniah, Mark S Shapses, Hani M. Babiker, Mohammad Umar Ahmed, Sreenivasa R Chandana |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Pharmacology
Oncology medicine.medical_specialty business.industry MEDLINE Cancer Drugs Investigational General Medicine Prognosis Precision medicine medicine.disease digestive system digestive system diseases Cholangiocarcinoma Clinical trial Bile Duct Neoplasms Drug Development Internal medicine Investigational Drugs Biomarkers Tumor medicine Humans Pharmacology (medical) Precision Medicine business |
| Zdroj: | Expert Opinion on Investigational Drugs. 30:1047-1056 |
| ISSN: | 1744-7658 1354-3784 |
| DOI: | 10.1080/13543784.2021.1985461 |
| Popis: | The development of novel biomarkers for cancer has exploded over the last decade with advances in novel technologies. Cholangiocarcinoma (CCA), a cancer of the bile ducts, has a dearth of strong disease and pathophysiology biomarkers, making early detection and prognostication a difficult task.In this comprehensive review, we discuss the spectrum of biomarkers for CCA diagnosis and prognostication. We elaborate on novel biomarker discovery through a comprehensive multi-omics approach. We also cover, how certain biomarkers may also serve as unique and potent targets for therapeutic development.Despite the relatively poor diagnostic and prognostic performance of existing biomarkers for CCA, there is a vast range of novel biomarkers with exquisite diagnostic and prognostic performance for CCA in the pipeline. Moreover, these biomarkers may serve as potential targets for precision medicine. Existing strategies to target unique biomolecular classes are discussed, within the context of an overall 'omics' focused profiling strategy. Omics profiling will simultaneously allow for enhanced biomarker development and identification of unique subtypes of cholangiocarcinoma and how they are influenced by an individual's unique context. In this manner, patient management strategy and clinical trial design can be optimized to the individual. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|